entertainment -WSS

entertainment

author：focus 2025-09-27 19:21:44 - browse：77

Chief executive officer of Sanofi Paul Hudson, wearing glasses, speaks into a mic — pharma coverage from STAT — Sanofi CEO Paul Hudson Carolyn Kaster/AP

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan.

“Would I have liked the stock market reaction to be more generous? Of course,” Hudson said at a Financial Times event in London. “But this is a long-term game, and if you’re trying to deliver long-term value, you try not to make too many short-term decisions.”

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. Company executives have argued that this was the moment — when Sanofi has a strong pipeline and isn’t facing patent expirations for years — to increase its R&D resources, even at the expense of short-term profits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Sage's campaign to raise awareness of postpartum depression hits a nerve

knowledge

Wikipedia

WSS

FDA approves Moderna’s RSV vaccine, its second licensed product

The painfully weak evidence on taking collagen to treat arthritis

How CO2 helps viruses stay alive longer in the air

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

STAT wants to know your pick for a great summer read or listen

Eli Lilly’s Zepbound improved liver scarring in mid

explore

entertainment

focus

Anesthesiologist group: stop taking Ozempic before surgery

ASCO Daily Recap: CAR

In Memoriam: Notable people who died in 2023

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

As demand for Covid shots wanes, Moderna seeks its next success

Sage's campaign to raise awareness of postpartum depression hits a nerve

In Memoriam: Notable people who died in 2023

Choosing scientific sides in the fight against Alzheimer's

BioMarin wins approval for gene therapy to treat hemophilia A

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

entertainment

Structure Therapeutics oral GLP

Lessons Learned: This is why you network to find that industry job you want

The most pressing bird flu mysteries scientists want answered

Elevance PBM president out as customers face prescription chaos

Structure Therapeutics oral GLP

Former Georgia lieutenant governor says he received grand jury subpoena

knowledge

entertainment

Wikipedia

hotspot